Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease.
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Obstructive Pulmonary Disease
- Sponsor
- Lund University
- Enrollment
- 75
- Locations
- 1
- Primary Endpoint
- Percentage of patients with elevated NT-proBNP.
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
The aim of the present study was to evaluate if the analysis of NT-proBNP might be used as an initial step for the diagnosis of chronic heart failure in patients with COPD in primary health care, and to select patients for a further examination by echocardiography.
Detailed Description
Patients with a confirmed diagnosis of COPD were examined regarding chronic heart failure. 1. An interview regarding symptoms: breathlessness, orthopnoea, night cough, nocturia, walking distance. 2. Physical examination: weight and height, heart and lung auscultation, blood pressure measurement after 5 minutes' rest in the sitting position and the presence of peripheral oedema. 3. Electrocardiography. 4. Natriuretic peptide- NT-proBNP (Immulite 2500, Siemens Healthcare Diagnostics AB Sweden). 5. Patients with the NT-proBNP level of \> 1200 pg/ml were referred for echocardiography to assess left ventricular function.
Investigators
Elzbieta Kaszuba
PhD student
Lund University
Eligibility Criteria
Inclusion Criteria
- •Patients aged 65 years and older with the following diagnosis codes according to International Statistical Classification of Diseases and Related Health Problems - Tenth Revision:J44 (COPD) and J41, J42 (chronic bronchitis) registered during the period 1 January 2008-16 April 2008 according to the electronic patient record.
Exclusion Criteria
- •Impaired cognitive function and/or anticipated difficulties in carrying out spirometry due to immobility,
- •psychiatric disorders or terminal illness.
Outcomes
Primary Outcomes
Percentage of patients with elevated NT-proBNP.
Time Frame: 3 months
NT-proBNP has taken only once in each patient without follow up follow up. Three months was a period when we collected data from all participants.
Secondary Outcomes
- Percentage of patients with abnormal left ventricular function assessed by echocardiography. Association between elevated NT-proBNP and symptoms, signs and electrocardiography.(3 months)